Worth Venture Partners’s Adamas Pharmaceuticals ADMS Stock Holding History

Worth Venture Partners’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-625,080	Closed	-$3.1M	–	160
2021 Q3	$3.1M	Buy	625,080 +34,350	+6%	+$167K	1.39%	22
2021 Q2	$3.12M	Buy	590,730 +52,335	+10%	+$271K	1.16%	31
2021 Q1	$2.58M	Buy	538,395 +313,289	+139%	+$1.64M	1.25%	24
2020 Q4	$975K	Hold	225,106	–	–	0.77%	38
2020 Q3	$927K	Sell	225,106 -18,600	-8%	-$72K	0.76%	34
2020 Q2	$624K	Buy	243,706 +86,564	+55%	+$254K	0.31%	51
2020 Q1	$454K	Buy	+157,142	New	+$704K	0.28%	52
2019 Q4	–	Sell	-77,384	Closed	-$396K	–	114
2019 Q3	$396K	Sell	77,384 -10,524	-12%	-$65K	0.23%	55
2019 Q2	$545K	Buy	87,908 +28,168	+47%	+$162K	0.3%	46
2019 Q1	$425K	Buy	+59,740	New	+$537K	0.24%	51

Worth Venture Partners's ADMS Position: Q4 2021 in Review

Worth Venture Partners sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 625,080 shares — an estimated $3.1M sold.

Worth Venture Partners first reported a position in ADMS in Q1 2019 and held it in 10 quarters. The position peaked at $3.12M in Q2 2021. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

Worth Venture Partners reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Worth Venture Partners sold 625,080 Adamas Pharmaceuticals shares in Q4 2021, an estimated $3.1M.
Worth Venture Partners first reported a position in Adamas Pharmaceuticals in Q1 2019 and held it in 10 quarters.
Worth Venture Partners's Adamas Pharmaceuticals position peaked at $3.12M in Q2 2021.
0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Worth Venture Partners's 13F filing for Q4 2021, filed 14 Feb 2022.